THERMO FISHER SCIENTIFIC INC. Annual Report, Year Ended Dec 31, 2019

Thermo Fisher Scientific Inc. reported strong performance for the fiscal year ending December 30, 2019, with total revenues reaching $25.54 billion, an increase of $1.18 billion from the prior year. This growth was driven by increased demand across its core end markets, particularly in the biotech and pharmaceutical sectors, despite some headwinds from currency translation and weaker end-market conditions in Asia during the fourth quarter. The company successfully executed its strategy of augmenting organic growth with strategic acquisitions, notably the acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, which expanded its contract manufacturing capabilities. Financially, the company demonstrated improved profitability, with operating income rising to $4.59 billion from $3.78 billion in the prior year, and an operating income margin of 18.0%, up from 15.5%. This was bolstered by the gain on the sale of the Anatomical Pathology business. Thermo Fisher maintains a solid liquidity position, with $2.40 billion in cash and cash equivalents and ample borrowing capacity, positioning it well to meet its financial obligations and fund future growth initiatives. The company's diversified business across four key segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services—and its commitment to innovation through R&D investments underscore its continued leadership in serving science.